Last reviewed · How we verify
NCT07096609: LONGIST
Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
Phase 1, PHASE2 trial testing Lenvatinib Capsules in GIST in 48 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Asan Medical Center |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 29 October 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Lenvatinib Capsules — full drug profile →
Conditions studied
- GIST — all drugs for GIST →
Sponsor
Asan Medical Center
Who can join
20 and older, any sex, with GIST. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the safety and efficacy of lenvatinib in patients with metastatic or advanced GIST who have failed at least imatinib, sunitinib, and regorafenib treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07096609
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lenvatinib Capsules
Trials testing the same drug.
- NCT06739395 — Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion · Phase 2 · recruiting
- NCT05101629 — Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based · Phase 2 · completed
Other recruiting trials for GIST
Currently open trials in the same condition.
- NCT07411118 — RCT of EFTR Versus STER for GIST Treatment · NA · recruiting
- NCT06640361 — A Study of Olverembatinib in SDH-deficient GIST. · Phase 3 · recruiting
- NCT05804331 — The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study · recruiting
- NCT03050268 — Familial Investigations of Childhood Cancer Predisposition · recruiting
Other Asan Medical Center trials
Trials by the same sponsor.
- NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
- NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
- NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
- NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
- NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07096609 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07096609.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing